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ABSTRACT
Volumetric-modulated arc therapy (VMAT) is increasingly popular as a treatment method in
radiotherapy owing to the speed with which treatments can be delivered. However, there has
been little investigation into the effect of increased modulation in lung plans with regard to
interfraction organ motion. This is most likely to occur where the planning target volume
(PTV) lies within areas of low density. This paper aims to investigate the effect of modulation
on the dose distribution using simulated patient movement and to propose a method that is less
susceptible to such movement. Simulated interfraction motion is achieved by moving the plan
isocentre in steps of 0.5 cm and 1.0 cm in six directions for five clinical VMAT patients. The
proposed planning method involves optimisation using a density override of 1 g cm23, within
the PTV in lung, to reduce segment boosting in the periphery of the PTV. This investigation
shows that modulation can result in an increase in the maximum dose of .25%, an increase in
PTV near-maximum dose of 17% and a reduction in near-minimum dose by 46%. Unacceptable
organ at risk (OAR) doses are also seen. The proposed method reduces modulation, resulting in
a maximum dose increase of 10%. Although safeguards are in place to prevent the increased
dose to OARs from patient movement, there is nothing to prevent the increased dose as a result
of modulation in lung. A simple planning method is proposed to safeguard against this effect.
Investigation suggests that, where modulation exists in a plan, this method reduces it and is
clinically viable.
Volumetric-modulated arc therapy (VMAT) is be-
coming increasingly popular as a treatment method
in radiotherapy owing to the speed with which
treatments can be delivered [1, 2] and the beneﬁt to
dose distribution. This beneﬁt is clear in patients
with concave planning target volumes (PTVs) near
organs at risk (OARs) [1, 3]. Several studies have
compared VMAT with intensity-modulated radio-
therapy and conventional plans for lung cancer with
a favourable outcome [4–7]. Although there have
been recent investigations into the effect of breath-
ing motion [8] and the interplay effect, there has
been little investigation into the effect of interfrac-
tion internal patient movement [9, 10] on the dose
distribution.
Where part of the PTV comprises air or low-density
tissue (i.e. lung), the optimiser attempts to boost the
dose to these regions to attain coverage with the 95%
isodose line despite the lack of tissue providing
scatter. This can result in highly modulated plans. This
“boosting” effect occurs owing to a lack of the scatter
material present in the beam and results in horns in
the ﬂuence proﬁle. The effect also occurs in situations
where any PTV is positioned near the patient’s skin
[11,p. 56–58].
The boosting effect is undesirable for two reasons.
Firstly, it is unnecessary to produce the same dose to
the PTV in air as the PTV in tumour tissue. As long as
the PTV in air is being exposed to the same ﬂuence
as the PTV in tissue, then the tumour grows or moves
into a region of air, the higher dose will follow it.
However, if the plan is modulated to boost the dose to
the PTV in air, then organ movement causes a de-
viation from the planning CT geometry, very high
doses can be seen in regions where tissue falls within
a boosted part of the beam. This may occur in lung
patients as the tumour regresses or owing to atelec-
tasis. In situations where daily imaging and breath-
hold devices or gating are not used, consideration
should be given as to whether it is appropriate to
deliver modulated VMAT plans for lung patients.
There are three options for avoiding unwanted modu-
lation in air in an optimised VMAT plan. Firstly, an
edited PTV can be used for optimising, which does not
extend fully into the lung, thus preventing the need for
any dose boosting in the lung. Alternatively, a bolus on
the skin surface can be used to provide scatter in order to
increase the dose to the skin region without boosting.
However, this is not applicable in the lung. A third al-
ternative is to optimise using a fake bolus, providing the
scatter material to prevent boosting, and then to remove
the bolus for the ﬁnal dose calculation of the clinical
plan. This results in poorer peripheral coverage near the
skin surface or in the lung, compared with using a real
bolus, but allows for patient movement within the fake
bolus region without any dose boosting. In conformal
plans, this could be achieved by pulling back multileaf
collimators (MLCs) or jaws.
This paper aims to investigate the effect of patient
movement on the dose distribution for the clinical
plan of ﬁve patients treated with a single VMAT arc.
An alternative method of planning is proposed using
a density override of the PTV in lung to 1 g cm23 (i.e. a
fake bolus) to reduce the boosting effect. This method is
investigated to determine whether it increases the safety
of modulated arc therapy in the case of internal organ
movement and uncertainties in patient set-up.
METHODS
Commonly, lung patients at our centre are planned
using in-house software (Autobeam [2]) that produces
a conformal arc. However, in cases where the PTV is
situated adjacent to or overlapping with the spinal cord
or other OAR, SmartArc (Pinnacle3 v. 9.0; Philips Ra-
diation Oncology Systems, Fitchburg, WI) is used to
meet the clinical objectives as it allows a more modu-
lated beam. This can result in increased modulation to
boost the dose to the PTV in lung. Single-arc SmartArc
plans were therefore used in this study.
Plans were optimised using SmartArc with leaf motion
constrained to 0.8 cm per degree. Patients were scanned
and treated using the active breathing coordinator [12]
device and were also imaged using cone-beam CT
(CBCT) for the ﬁrst three fractions and then weekly
thereafter. In this study, ﬁve clinical patient plans were
reviewed. The location and size of the PTV for each pa-
tient can be found in Table 1.
Assessing the robustness of VMAT for lung
Patient movement was simulated using an isocentre-
shift method with shifts of 0.5 cm and 1 cm in the
anterior–posterior, superior–inferior and left–right
directions. The availability of CBCT online correction
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makes this an unlikely clinical scenario but the method
is sufﬁcient to simulate the effect of internal structure
movement that is less easily corrected for [12]. Each
clinical plan was then applied to the shifted isocentres
by ﬁxing the monitor units and recalculating. Plans
were calculated on a rectangular dose grid of 0.25 cm
resolution using the Pinnacle adaptive convolution al-
gorithm. The PTV D2, D98 and D50 and maximum
point dose in the plan were recorded for each shift and
for the original clinical plan to determine the impact of
the change in anatomy. The lung V20, lung mean dose
and spinal cord maximum dose were also recorded.
PTV D2 and D98 are the near-maximum and near-
minimum doses, respectively, reported in accordance
with recommendations made in International Com-
mission on Radiation Units and Measurements (ICRU)
report 83 [11], along with the median absorbed dose,
PTV D50. Lung V20 is the volume of lung minus gross
tumour volume (GTV) that receives 20Gy.
Proposed planning method
The boosting effect occurs as the beam is modulated to
provide dosimetric coverage by the 95% isodose of the
PTV in lung. The proposed solution involved creating
a new region of interest comprising the PTV within lung
(i.e. within very low-density tissue) and overriding the
density of this region to 1 g cm23. The plans were opti-
mised with the prescription to the mean of the PTV with
this density override on. Plans were considered clinically
acceptable when the OAR constraints were met. The time
for delivery was limited to the minimum allowed for the
gantry to do a full rotation (68 s) to limit MLC move-
ment. The density override was then removed for the
ﬁnal dose calculation. Each plan was subsequently repre-
scribed to the PTV in tissue (deﬁned as the PTV–PTV in
lung), labelled PTVp. The same isocentre-shift method
was then used to assess the impact of interfraction motion.
RESULTS
Assessing the robustness of VMAT for lung
The maximum point dose in the plan, as a percentage
of the prescribed dose, is shown for each isocentre-shift
plan in Figure 1, along with the PTV D98, lung V20 and
spinal cord maximum dose. The results vary consider-
ably between patients. The graph for Patient 1 dem-
onstrates dose boosting up to 138% of the prescribed
dose (i.e. 82.6Gy, an increase from the clinical plan
maximum dose of 16.5Gy) with a 1-cm shift. The
graph for Patient 3 shows no boosting whatsoever as the
maximum dose remains almost constant at 103% of the
prescribed dose.
As could be expected, shifting the isocentre results in
poorer coverage of the PTV as shown in the D98
graph. The worst case for most patients was a 1-cm
shift inferiorly, resulting in a D98 of ,55% of the
prescribed dose for two of the patients, compared
with .90% for both clinical plans. The cord maxi-
mum dose and lung V20 are very dependent on the
position of the PTV. The tumour for Patient 2 was
located in the middle of the left lung resulting in
a higher V20. However, this was not greatly affected
by isocentre shifts, whereas the cord dose rose as high
as 63 Gy.
Proposed planning method
The dose distribution for the clinical plan produced
using the proposed planning method was compared
with the original plan (Figure 2). Represcribing to
the mean of the PTV in tissue once the density
override was removed resulted in a reduction in
monitor units of on average 0.4% (20.57% to 2
0.24%) compared with the optimised plan. In each
case, the ﬁnal clinical plan was clinically acceptable.
It was possible to keep all OAR doses within con-
straints even with the reduced delivery time. Table 2
Table 1. Size and position of the planning target volume (PTV) for each patient. Prescription is to the mean of the PTV
Patient PTV (ml) PTV location PTV in lung (%) Prescription (Gy)
1 273 Superior right post 33 60
2 297 Medial/left post 34 64
3 252 Superior left post 47 64
4 266 Superior right post 27 60
5 342 Superior left post 30 64
Post, posterior.
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demonstrates the dose to normal tissues for the new
method.
Figure 3 shows the variation in the maximum per-
centage dose for the isocentre-shifted plans for the
proposed planning method. There is a general im-
provement in the amount of variation in the maxi-
mum dose compared with the original planning
method. There is a marked improvement in the dose
boosting for Patient 1 compared with the original
plan, with the maximum dose now 115% of the
prescribed dose. An improvement is also seen for
Patient 2. The new method produced a higher dose
for the clinical plan of Patient 3. However, there is no
high dose above 105% of the prescribed dose for any
of the shifts. The results for Patient 4 showed no
difference in the maximum dose between the plan-
ning methods. The clinical plan for Patient 5 was
actually improved using the new planning method as
a hotspot was removed and the maximum point dose
dropped from 109% to 105%. Figure 3 shows that
there was also less of an increase when the plan was
shifted, as the new plan was less modulated than the
original clinical plan.
There is no substantial difference between the variation
in the cord dose, lung V20 and PTV D98 for the
original and proposed plans. However, the D98 is lower
for the proposed clinical plans. The dose distribution
was not expected to cover the PTV in lung with the
95% isodose owing to the lack of dense tissue; however,
if the GTV had moved within this region, the 95%
isodose would follow it while it remained within the
PTV. This is because the GTV is relatively dense tissue.
DISCUSSION
This study was designed to determine the effect of
modulation on the dose distribution in the case of in-
ternal anatomical movement. There was some variation
in the amount of modulation of the plans and the re-
sultant boosting effect that was seen. This is to be
expected owing to the varying size and shape of the
lung tumour and the PTV and its location within the
lung as well as the amount of lung within the PTV.
Clearly, patient movement should be minimised or
taken into account during delivery as far as is reason-
ably possible. This study demonstrated unacceptable
OAR doses for some patients when isocentre shifts were
Figure 1. Effect of patient movement on the planning target volume (PTV) D98, maximum delivered dose, lung V20
and spinal cord maximum dose. Lines are to guide the eye; they are not intended to indicate a trend. ant, anterior; inf,
inferior; post, posterior; pt, patient; sup, superior.
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applied, particularly in the cases where the PTV was
situated adjacent to the spinal cord. This is to be ex-
pected as large shifts of 0.5 cm and 1 cm were used. A
planning OAR volume is used during planning to ac-
count for uncertainties in positioning. CBCT is also
used and registration is to bony landmarks, speciﬁcally
the spinal canal. The PTV should account for this un-
certainty in set-up and movement around the clinical
target volume [11]. However, none of these methods
can completely account for anatomical changes. Con-
sequently, a planning method is proposed to improve
the robustness of VMAT for lung patients.
The proposed method is similar to the fake bolus
method discussed in ICRU report 83 [11]. Optimising
to the tumour tissue volume would not allow for do-
simetric coverage if the tissue moved within the PTV in
lung, and a real bolus is not a realistic option within the
lung. The proposed method is to override the density of
the PTV in lung (PTVp) during optimisation. This
method resulted in a more stable dose distribution
during organ movement and was simple to implement
with very little additional planning time required. The
proposed method produced a higher dose in the new
plan for Patient 3 than the original clinical plan because
the plan was optimised with a density override in place.
This highlights the lack of control in the ﬁnal plan as
the optimising is done before the density override is
removed. However, this resulted in a very small increase
in the dose that was consistent across all isocentre shifts
Figure 2. Original clinical plan for Patient 1 (a), and the proposed new plan with density override switched off (b). Bold
isodose represents 95% of the prescribed dose.

















1 45.05 45.20 5.65 5.30 10 9
2 45.21 44.83 16.80 17.22 29 29
3 39.88 43.83 11.92 12.38 21 22
4 45.23 45.74 6.67 6.87 9 10
5 47.25 45.38 6.38 6.60 10 10
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showing no dose boosting. Therefore, if a plan is clin-
ically acceptable, then this is not an issue.
As a result of reviewing these ﬁve patients, this method
could be clinically implemented as a more robust VMAT
plan. However, lung patients requiring a SmartArc plan
at our centre are relatively rare. In the case of such
a patient, it is suggested that the plan with the density
override on is also reviewed by the clinician to ensure
that the expected coverage in the case of GTV move-
ment within the PTV is good. This study addresses the
issue of modulation in SmartArc plans only. It would be
worthwhile investigating this effect in other planning
systems as well and potentially extending the imple-
mentation of the proposed method.
CONCLUSION
This paper investigates the effect of modulation on the
dose distribution in lung SmartArc plans by using
simulated patient movement. Shifting the isocentre to
simulate organ motion gives on average a 2% increase
in the maximum dose. The largest increase in the
maximum point dose is 28%. Lung V20 varies by 0%
on average, with a maximum increase of 2% (from 10%
to 12%). The maximum cord dose increases up
to 63Gy with an average maximum dose of 46.2Gy.
A new method has been devised to reduce the possi-
bility of delivering an unknown high dose in the event of
internal patient movement and the results seen using the
isocentre-shift method suggest that it is effective. The
maximum cord dose is 64.2Gy with an average of
47.3Gy. This increase in the cord dose is likely to be
a result of moving the high-dose volume towards the
spinal cord rather than any boosting of the dose resulting
from changes to the modulation in the PTV. The lung
V20 mean variation is 0% with a maximum increase of
2% (from 9% to 11%). The mean increase in the
maximum dose over all ﬁve patients is reduced to 0.5%.
The largest increase in the maximum point dose is re-
duced to 10% for the proposed new planning method.
There is a general reduction in the amount of modu-
lation where modulation exists in the original plan. In
those patients in whom there is little MLC leaf motion,
there is no beneﬁt of using this method. This new
method is simple to implement and does not require
additional planning time.
Figure 3. Effect of patient movement on the planning target volume (PTV) D98, maximum delivered dose, lung V20
and spinal cord maximum dose for the proposed planning method. Lines are to guide the eye; they are not intended
to indicate a trend. Same scale as in Figure 1. ant, anterior; inf, inferior; post, posterior; pt, patient; sup, superior.
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